Onco Therapies is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. The Company's first clinical asset, OT-043, is based on the scientific team's core understanding of CD4 depletion and its anti-tumor immune response. Onco's scientific research team has been at the forefront of this discovery and is targeting to initiate a Phase Ib/IIa clinical trial in 2019.